Peptide therapeutics for rare genetic metabolic diseases


Rhythm Therapeutics (NASDAQ: RYTM) is a biopharmaceutical company focused on developing peptide therapeutics for the treatment of rare genetic deficiencies that result in life‑threatening metabolic disorders. Rhythm’s lead peptide product candidate is setmelanotide, a first‑in‑class melanocortin‑4 receptor, or MC4R, agonist for the treatment of rare genetic disorders of obesity.


Year Invested: 2010
Location: Boston, Mass.
Visit: www.rhythmtx.com

Recent News

January 4, 2018
Rhythm Pharmaceuticals Announces Progress in Clinical Development of Setmelanotide for Treatment of Rare Genetic Disorders of Obesity

November 14, 2017
Rhythm Pharmaceuticals Reports Third Quarter 2017 Financial Results

October 31, 2017
Rhythm Announces Preliminary Data from Phase 2 Study of Setmelanotide for Treatment of Bardet-Biedl Syndrome

Read More News

Associated Team Members

Neil Exter
Partner